[Cerebral ischaemia: tomorrow's therapeutic tracks].
Thrombolysis remains the main therapeutic strategy used in stroke, but with a limited use to only a part of stroke patients. A neuroprotective approach would be necessary with a double objective : (1) to serve as an add-on treatment with thrombolysis to improve safety and increase therapeutic window ; (2) to limit infarct area by delaying neuronal death. While numerous molecules failed in clinical trials in stroke, pharmacological development is on-going with pleiotropic drugs targeting both neuronal and vascular parts of neurovascular unit. Another approach targets the functional rehabilitation and the neurorepair using pharmacological ways or cell therapy.
EA1046, département de pharmacologie médicale, Institut de médecine prédictive et de recherche thérapeutique, Université Lille-Nord de France, Faculté de médecine, Centre hospitalier et universitaire de Lille, 2, avenue Oscar Lambret 59037 Lille Cedex, France. r-bordet@chru-lille.fr
Régis
R
Bordet
Thavarak
T
Ouk
Brigitte
B
Onténiente
Christiane
C
Charriaut-Marlangue
Catherine
C
Heurteaux
D017209:Apoptosis; D001253:Astrocytes / Q000502:physiology; D001393:Azoles / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy / Q000628:therapy*; D002544:Cerebral Infarction / Q000473:pathology / Q000517:prevention & control; D003937:Diagnosis, Differential; D004730:Endothelium, Vascular / Q000503:physiopathology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D054833:Isoindoles; D009474:Neurons / Q000473:pathology / Q000502:physiology; D018696:Neuroprotective Agents / Q000627:therapeutic use; D016566:Organoselenium Compounds / Q000627:therapeutic use; D015424:Reperfusion; D009435:Synaptic Transmission / Q000502:physiology
D001393:Azoles; D054833:Isoindoles; D018696:Neuroprotective Agents; D016566:Organoselenium Compounds; D016179:Granulocyte Colony-Stimulating Factor; C042986:ebselen